Evidence of β-blockers drug repurposing for the treatment of triple negative breast cancer: A systematic review

Triple negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer (BC) for which limited therapeutic options are available. Recently, β-blockers (BBs) have been suggested to have favorable effects in the treatment of BC. The aim of this systematic review was to collect evidence from preclinical and clinical studies concerning the scientific evidence for the repurposing of BBs in TNBC treatment. PubMed database was searched to retrieve studies of interest published up to 30/01/2018. All preclinical studies using TNBC in vitro and in vivo models and assessing the effect of any molecule with sympatholytic or sympathomimetic activity on adrenergic receptors were included. Clinical studies concerning BBs were considered eligible. The Newcastle-Ottawa scale was used for the quality assessment of clinical studies. A total of 614 study references were retrieved. Forty-six preclinical studies were included. In in vitro studies, propranolol, a non-selective BB, significantly decreased proliferation, migration and invasion of TNBC cells. Consistently, in in vivo studies, propranolol inhibited metastasis, angiogenesis and tumor growth. Clinical studies, reporting evidence from a total of four distinct retrospective observational cohort studies, showed a beneficial effect of BBs in TNBC treatment. The overall quality of the clinical evidence collected was low. Preclinical evidence collected in this systematic review are in line with the results reported in the clinical studies retrieved, pointing towards a beneficial effect of BB in the treatment of TNBC. However, given the overall low quality of available evidence, no definite conclusion may be drawn.

Abstract P3-14-08: Preclinical and clinical evidence about the use of betablockers for the treatment of triple negative breast cancer: A systematic review

Introduction

Triple negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer (BC) for which very limited therapeutic options are available. Recently, beta-blockers (BB) have been suggested to have favorable effects on the treatment of BC both in preclinical and clinical studies.

Objective

The aim of this systematic review was to collect evidence from preclinical and clinical studies concerning the scientific evidence for the repurposing of BBs in TNBC treatment.

Methods

PubMed database was searched for retrieving studies of interest published up to 30/01/2018. All preclinical studies using BC in vitro and in vivo models and assessing the effect of any molecule with sympatholytic or sympathomimetic activity on adrenoceptors were included. Clinical studies concerning BB were considered eligible. Two authors independently reviewed and screened title and abstract of retrieved references. Potentially relevant studies were further assessed through full-texts examination. One author extracted information from preclinical and clinical studies respectively. A second author subsequently reviewed the extracted data. The Newcastle-Ottawa scale was used for the quality assessment of clinical studies.

Results

A total of 616 study references were initially retrieved. Six additional records were retrieved through snowball search. A total of 62 preclinical studieswere included, of which 46 concerned in vitro and in vivo models of TNBC, i.e. cell cultures and/or animal studies (20 in vitro, 9 in vivo, and 17 in vivo/vitro). In vitro studies showed a high expression of β2 adrenoreceptors in TNBC cell lines. Propranolol, a non-selective β1/β2 antagonist, was reported to significantly decrease proliferation, migration and invasion of TNBC cells. Similar effects were also reported for carvedilol, a selective β2 antagonist and α1 antagonist. In vivo studies reported a reduction of metastasis, angiogenesis and tumor growth in animals exposed to propranolol..Clinical studies, reporting evidence from a total of four distinct retrospective observational cohort studies, showed a beneficial effect of BB in TNBC treatment: e.g. study#1: Overall Survival Hazard Ratio (HR)=0.35 (95%CI 0.12-1.00); study#2: metastasis HR=0.32 (95%CI 0.12–0.90); study3# Progression Free Survival: HR=0.52 (95%CI 0.34–0.79); study #4 Relapse Free Survival: HR=0.69 (95%CI 0.35–1.34). The overall quality of the clinical evidence collected was low.

Conclusion:

Preclinical evidence collected in this systematic review are in line with the results reported in the four clinical studies retrieved, pointing towards a beneficial effect of BB in the treatment of TNBC. However, given the overall low quality of available evidence, no definite conclusion may be drawn. The execution of large scale interventional clinical studies are warranted to shed light on the efficacy/effectiveness of BB in TNBC treatment.

Aknowledgment:

This study was supported by Fondazione decima regio “Olga e Raimondo Curri”

Citation Format: Spini A, Roberto G, Gini R, Bartolini C, Bazzani L, Donnini S, Crispino S, Ziche M. Preclinical and clinical evidence about the use of betablockers for the treatment of triple negative breast cancer: A systematic review [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-14-08.

The Effect of Two Office Ergonomics Field Interventions and their Replication on Visual Symptoms

Upper extremity musculoskeletal symptoms and disorders in the workplace continue to be a significant public health burden (National Research Council and Institute of Medicine, 2001). These outcomes, as they relate to computer use, are important as greater than 50% of employed adults in the United States use a computer at work (U.S. Census Bureau, 2003). Visual symptoms are also known to often coexist with upper extremity musculoskeletal symptoms with computer workers. This study examines the effect of two office ergonomic interventions, a highly adjustable chair and an office ergonomics training, on the reduction of specific visual symptoms. Additionally, findings from a replicated study site are compared with those of the original study. Multilevel logistic regression models were used to estimate the effect. In comparing the original and replication worksites we find specific visual symptom reductions occurred for the group receiving both the chair with training at the original and replicated worksite. However, the group receiving only the office ergonomics training experienced individual visual symptom reductions at the replication worksite but not the original worksite. There were differences in the specific visual symptoms affected by the office ergonomics interventions when comparing worksites.

A replicated field intervention study evaluating the impact of a highly adjustable chair and office ergonomics training on visual symptoms

OBJECTIVE

Examine the effects of two office ergonomics interventions in reducing visual symptoms at a private sector worksite.

METHODS

A quasi-experimental study design evaluated the effects of a highly adjustable chair with office ergonomics training intervention (CWT group) and the training only (TO group) compared with no intervention (CO group). Data collection occurred 2 and 1 month(s) pre-intervention and 2, 6 and 12 months post-intervention. During each data collection period, a work environment and health questionnaire (covariates) and daily health diary (outcomes) were completed. Multilevel statistical models tested hypotheses.

RESULTS

Both the training only intervention (p<0.001) and the chair with training intervention (p=0.01) reduced visual symptoms after 12 months.

CONCLUSION

The office ergonomics training alone and coupled with a highly adjustable chair reduced visual symptoms. In replicating results from a public sector worksite at a private sector worksite the external validity of the interventions is strengthened, thus broadening its generalizability.

A field intervention examining the impact of an office ergonomics training and a highly adjustable chair on visual symptoms in a public sector organization

OBJECTIVE

Examine the effect of a multi-component office ergonomics intervention on visual symptom reductions.

METHODS

Office workers were assigned to either a group receiving a highly adjustable chair with office ergonomics training (CWT), a training-only group (TO) or a control group (C). A work environment and health questionnaire was administered 2 and 1 month(s) pre-intervention and 3, 6, and 12 months post-intervention. Multi-level statistical models tested hypotheses.

RESULTS

The CWT intervention lowered daily visual symptoms (p < 0.01) post-intervention. The TO group did not significantly differ from the control group. The CWT group differed significantly from the TO group (p = 0.01) post-intervention.

CONCLUSION

Workers who received a highly adjustable chair and office ergonomics training had reduced visual symptoms and the effect was maintained through twelve months post-intervention. The lack of a training-only group effect supports implementing training in conjunction with the highly adjustable chair to reduce visual symptoms.

The effects of an office ergonomics training and chair intervention on worker knowledge, behavior and musculoskeletal risk

A large-scale field intervention study was undertaken to examine the effects of office ergonomics training coupled with a highly adjustable chair on office workers' knowledge and musculoskeletal risks. Office workers were assigned to one of three study groups: a group receiving the training and adjustable chair (n=96), a training-only group (n=63), and a control group (n=57). The office ergonomics training program was created using an instructional systems design model. A pre/post-training knowledge test was administered to all those who attended the training. Body postures and workstation set-ups were observed before and after the intervention. Perceived control over the physical work environment was higher for both intervention groups as compared to workers in the control group. A significant increase in overall ergonomic knowledge was observed for the intervention groups. Both intervention groups exhibited higher level behavioral translation and had lower musculoskeletal risk than the control group.

Effect of office ergonomics intervention on reducing musculoskeletal symptoms

STUDY DESIGN

Office workers invited and agreeing to participate were assigned to one of three study groups: a group receiving a highly adjustable chair with office ergonomics training, a training-only group, and a control group receiving the training at the end of the study.

OBJECTIVE

To examine the effect of office ergonomics intervention in reducing musculoskeletal symptom growth over the workday and, secondarily, pain levels throughout the day.

MATERIALS AND METHODS

Data collection occurred 2 months and 1 month before the intervention and 2, 6, and 12 months postintervention. During each round, a short daily symptom survey was completed at the beginning, middle, and end of the workday for 5 days during a workweek to measure total bodily pain growth over the workday. Multilevel statistical models were used to test hypotheses.

RESULTS

The chair-with-training intervention lowered symptom growth over the workday (P = 0.012) after 12 months of follow-up. No evidence suggested that training alone lowered symptom growth over the workday (P = 0.461); however, average pain levels in both intervention groups were reduced over the workday.

CONCLUSION

Workers who received a highly adjustable chair and office ergonomics training had reduced symptom growth over the workday. The lack of a training-only group effect supports implementing training in conjunction with highly adjustable office furniture and equipment to reduce symptom growth. The ability to reduce symptom growth has implications for understanding how to prevent musculoskeletal injuries in knowledge workers.